Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, PR China.
J Neurosci Res. 2024 Jan;102(1):e25254. doi: 10.1002/jnr.25254. Epub 2023 Oct 10.
Ivermectin (IVM), a semi-synthetic macrolide parasiticide, has demonstrated considerable effectiveness in combating internal and external parasites, particularly nematodes and arthropods. Its remarkable ability to control parasites has earned it significant recognition, culminating in Satoshi Omura and William C. Campbell's receipt of the 2015 Nobel Prize in Physiology or Medicine for their contributions to the development of IVM. In recent years, investigations have revealed that IVM possesses antitumor properties. It can suppress the growth of various cancer cells, including glioma, through a multitude of mechanisms such as selective targeting of tumor-specific proteins, inducing programmed cell death, and modulation of tumor-related signaling pathways. Hence, IVM holds tremendous potential as a novel anticancer drug. This review seeks to provide an overview of the underlying mechanisms that enable IVM's capacity to suppress glioma. Furthermore, it aims to elucidate the challenges and prospects associated with utilizing IVM as a new anticancer agent.
伊维菌素（IVM）是一种半合成大环内酯类驱虫药，在对抗内部和外部寄生虫方面具有相当大的效果，特别是线虫和节肢动物。它控制寄生虫的能力非常出色，因此 Satoshi Omura 和 William C. Campbell 因对 IVM 的开发做出贡献而获得 2015 年诺贝尔生理学或医学奖。近年来的研究表明，IVM 具有抗肿瘤特性。它可以通过多种机制抑制包括神经胶质瘤在内的各种癌细胞的生长，如选择性靶向肿瘤特异性蛋白、诱导程序性细胞死亡和调节肿瘤相关信号通路。因此，IVM 作为一种新型抗癌药物具有巨大的潜力。本综述旨在概述使 IVM 能够抑制神经胶质瘤的潜在机制。此外，还旨在阐明将 IVM 用作新型抗癌剂所面临的挑战和前景。
